---
title: "Key facts: Merck KGaA to Buy Bio-Techne; Break Fees $576M/$230M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291023819.md"
description: "Merck KGaA to buy Bio-Techne to boost lab‑tools, cell/gene therapy and precision‑medicine capabilities, aiming for scale as biotech funding slows and R&D spending is expected to recover 1Merck KGaA would owe a $576.1M break fee to Bio-Techne if the merger ends under certain conditions; Bio-Techne would owe Merck $230.5M per the filing. 2"
datetime: "2026-06-27T05:13:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291023819.md)
  - [en](https://longbridge.com/en/news/291023819.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291023819.md)
generator: "portal-rs"
---

# Key facts: Merck KGaA to Buy Bio-Techne; Break Fees $576M/$230M

-   Merck KGaA to buy Bio-Techne to boost lab‑tools, cell/gene therapy and precision‑medicine capabilities, aiming for scale as biotech funding slows and R&D spending is expected to recover 1
-   Merck KGaA would owe a $576.1M break fee to Bio-Techne if the merger ends under certain conditions; Bio-Techne would owe Merck $230.5M per the filing. 2

### Related Stocks

- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [MRK.DE](https://longbridge.com/en/quote/MRK.DE.md)
- [MKKGY.US](https://longbridge.com/en/quote/MKKGY.US.md)

## Related News & Research

- [TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders](https://longbridge.com/en/news/296677873.md)
- [Bio-Techne’s Restrictive Merger Terms and Heavy Termination Fee Threaten Competitive Bidding and Future Deal Leverage](https://longbridge.com/en/news/296994108.md)
- [Crown Capital Provides Bi-Weekly MCTO Default Status Report](https://longbridge.com/en/news/296957450.md)
- [Valion Bio announces 1-for-25 reverse stock split effective Aug. 31](https://longbridge.com/en/news/297186352.md)
- [Pentwater Capital Management LP Takes Position in Bio-Techne Corp $TECH](https://longbridge.com/en/news/297162508.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**